InBody Co.Ltd
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was foun… Read more
InBody Co.Ltd (041830) - Total Liabilities
Latest total liabilities as of September 2025: ₩36.31 Billion KRW
Based on the latest financial reports, InBody Co.Ltd (041830) has total liabilities worth ₩36.31 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
InBody Co.Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how InBody Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
InBody Co.Ltd Competitors by Total Liabilities
The table below lists competitors of InBody Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
S.Biomedics Co. Ltd.
KQ:304360
|
Korea | ₩33.89 Billion |
|
Sansec Technology Co. Ltd. A
SHG:688489
|
China | CN¥178.89 Million |
|
Ganzhou Yihao New Materials Co. Ltd. A
SHE:301176
|
China | CN¥1.36 Billion |
|
Beijing Bashi Media Co Ltd
SHG:600386
|
China | CN¥2.50 Billion |
|
Chongqing QinAn M&E PLC
SHG:603758
|
China | CN¥320.30 Million |
|
Strata Critical Medical, Inc.
NASDAQ:SRTA
|
USA | $52.08 Million |
|
Suzhou Cheersson Precision Metal Fo
SHE:002976
|
China | CN¥1.53 Billion |
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
China | CN¥1.02 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down InBody Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InBody Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InBody Co.Ltd (2011–2024)
The table below shows the annual total liabilities of InBody Co.Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩31.91 Billion | +29.61% |
| 2023-12-31 | ₩24.62 Billion | -10.16% |
| 2022-12-31 | ₩27.41 Billion | +36.85% |
| 2021-12-31 | ₩20.03 Billion | +24.49% |
| 2020-12-31 | ₩16.09 Billion | +5.75% |
| 2019-12-31 | ₩15.21 Billion | +108.38% |
| 2018-12-31 | ₩7.30 Billion | +31.58% |
| 2017-12-31 | ₩5.55 Billion | +16.54% |
| 2016-12-31 | ₩4.76 Billion | -23.37% |
| 2015-12-31 | ₩6.21 Billion | +74.47% |
| 2014-12-31 | ₩3.56 Billion | +68.39% |
| 2013-12-31 | ₩2.11 Billion | +4.24% |
| 2012-12-31 | ₩2.03 Billion | +19.02% |
| 2011-12-31 | ₩1.70 Billion | -- |